Business briefs: UCB, Amgen, Novo Nordisk

February 13 2013

UCB, Amgen dump bone fracture drug amid tighter regs; Tresiba wins approval in Japan; DiabeticConnect tops diabetes sites

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.